DNA Methylation and Birth Weight:a Genome-wide Analysis

MAO Li Li XIAO Xin Hua ZHANG Qian ZHENG Jia LI Wen Hui YU Miao ZHANG Hua Bing PING Fan XU Jian Ping WANG Xiao Jing

MAO Li Li, XIAO Xin Hua, ZHANG Qian, ZHENG Jia, LI Wen Hui, YU Miao, ZHANG Hua Bing, PING Fan, XU Jian Ping, WANG Xiao Jing. DNA Methylation and Birth Weight:a Genome-wide Analysis[J]. Biomedical and Environmental Sciences, 2017, 30(9): 667-670. doi: 10.3967/bes2017.088
Citation: MAO Li Li, XIAO Xin Hua, ZHANG Qian, ZHENG Jia, LI Wen Hui, YU Miao, ZHANG Hua Bing, PING Fan, XU Jian Ping, WANG Xiao Jing. DNA Methylation and Birth Weight:a Genome-wide Analysis[J]. Biomedical and Environmental Sciences, 2017, 30(9): 667-670. doi: 10.3967/bes2017.088

doi: 10.3967/bes2017.088
基金项目: 

This project was supported by the National Natural Science Foundation of China (NSFC), project number is 81170736

This project was supported by the National Natural Science Foundation of China (NSFC), project number is 81570715

DNA Methylation and Birth Weight:a Genome-wide Analysis

Funds: 

This project was supported by the National Natural Science Foundation of China (NSFC), project number is 81170736

This project was supported by the National Natural Science Foundation of China (NSFC), project number is 81570715

More Information
    Author Bio:

    MAO Li Li, female, MM, majoring in the pathogenesis of diabetes

    Corresponding author: XIAO Xin Hua, Professor, Tel:86-10-69155073, E-mail:xiaoxinhua@medmail.com.cn
图(1) / 表ll (3)
计量
  • 文章访问数:  1667
  • HTML全文浏览量:  481
  • PDF下载量:  71
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-06-01
  • 录用日期:  2017-08-29
  • 刊出日期:  2017-09-01

DNA Methylation and Birth Weight:a Genome-wide Analysis

doi: 10.3967/bes2017.088
    基金项目:

    This project was supported by the National Natural Science Foundation of China (NSFC), project number is 81170736

    This project was supported by the National Natural Science Foundation of China (NSFC), project number is 81570715

    作者简介:

    MAO Li Li, female, MM, majoring in the pathogenesis of diabetes

    通讯作者: XIAO Xin Hua, Professor, Tel:86-10-69155073, E-mail:xiaoxinhua@medmail.com.cn

English Abstract

MAO Li Li, XIAO Xin Hua, ZHANG Qian, ZHENG Jia, LI Wen Hui, YU Miao, ZHANG Hua Bing, PING Fan, XU Jian Ping, WANG Xiao Jing. DNA Methylation and Birth Weight:a Genome-wide Analysis[J]. Biomedical and Environmental Sciences, 2017, 30(9): 667-670. doi: 10.3967/bes2017.088
Citation: MAO Li Li, XIAO Xin Hua, ZHANG Qian, ZHENG Jia, LI Wen Hui, YU Miao, ZHANG Hua Bing, PING Fan, XU Jian Ping, WANG Xiao Jing. DNA Methylation and Birth Weight:a Genome-wide Analysis[J]. Biomedical and Environmental Sciences, 2017, 30(9): 667-670. doi: 10.3967/bes2017.088
  • It is thought that intrauterine environment may impact the conceptus (i.e., the embryo/fetus and associated extra-embryonic membranes) during 'critical periods' of rapid cell division, thereby altering the expression of the fetal genome. Increasing evidence[1-2]suggests that complex interactions between genes and the environment play a major role in many common human diseases, such as diabetes, through the involvement of epigenetic factors, which occur without alterations in the DNA sequence.

    DNA methylation at promoter CpG islands has been associated with gene repression and is a well-studied epigenetic marker in the context of tumor suppressor genes and cancer[3]. A recent study has shown that intrauterine growth retardation can lead to T2D due to epigenetic silencing of Pdx1, a key transcription factor that regulates INS expression and beta cell differentiation. Another study[4] compared rats that were subjected to intrauterine growth restriction (IUGR) to normal rats at 7 weeks of age-prior to the onset of diabetes; this study revealed changes in DNA methylation at a number of novel loci that were not limited to canonical CpG islands or promoters. However, the role of these modifications is unknown. Some research[5-6] has indicated that low birth weight is an independent risk factor for developing type 2 diabetes. Therefore, can epigenetic changes be linked to differences in birth weight? Thus, this study aims to explore the global DNA methylation analysis of infants of different birth weights.

    This study was approved by the Ethics Committee of the Peking Union Medical College Hospital (S-002). Written informed consent was obtained from all subjects prior to participation.

    Cord blood samples and placenta samples were obtained from women attending the Maternity Unit of the Peking Union Medical College Hospital between July 2009 and January 2010. Demographic data regarding maternal medical history, age at delivery, parity, body mass index pre-pregnancy, pregnancy complications, newborn gender, gestational age, birth weight, and body length were recorded. Inclusion criteria include single fetus full-term newborns, maternal health, and no smoking or drinking history. Birth weight was used to identify cases and controls: low birth weight (LBW, birth weight < 3, 000 g), normal birth weight (NBW, birth weight ≥ 3, 000 g and < 4, 000 g), and high birth weight (HBW, birth weight ≥ 4, 000 g). We consider NBW as control group, and LBW, HBW as cases. Gestational age at delivery, gender, mother's age and pre-pregnancy BMI were matched, resulting in the inclusion of 9 cases in the study. The demographic characteristics of the 9 subjects are provided in Table 1.

    Table 1.  Demographic Characteristics of the Infants

    No.GenderGestational
    Age(W)
    Birth
    Weight(g)
    Length
    (cm)
    Head
    Circum-ference(cm)
    Placental
    Weight(g)
    L1M372, 2104529490
    L2F372, 3804632545
    L3M39+12, 5204733.6500
    N1M38+63, 2504933.5540
    N2M38+63, 2505134660
    N3F39+53, 2604935655
    H1M41+54, 4105135850
    H2M384, 5105234.8955
    H3F40+34, 7755232.51, 150
    P(Lvs.N)0.00060.00740.0428
    P(Hvs.N)0.000070.000790.0088
      Note.L: low birth weight infant, N: normal birth weight infant, H: high birth weight infant, M: male, F: female.

    DNA was extracted from cord blood samples and placenta samples. DNA samples from the cases and controls were interrogated using the Illumina Infinium® Human Methylation27 BeadChip. Then We used the Methylation Module of Illumina Genome Studio software for differential methylation analysis. The differentially methylated gene sets were used to identify enriched KEGG pathways with the functional enrichment analysis software package Web-based Gene Set Analysis Toolkit (WebGestalt). Glucose metabolism is a complex process that involves many metabolic pathways, such as lipid metabolism, fatty acid metabolism, glycerolipid metabolism, carbohydrate metabolism, glycolysis/ gluconeogenesis, mTOR signaling, and adipocytokine signaling. This study focused on the methylation level of the genes involved in these pathways. To understand the interactions and dependencies among the critical pathways, we generated a network model based on the relationships in the KEGG database.

    Characteristics of the subjects are summarized in Table 1. Nine healthy full-term infants were enrolled. All infants were divided into three groups according to birth weight: low birth weight (LBW, birth weight < 3, 000 g), normal birth weight (NBW, birth weight ≥ 3, 000 g and < 4, 000 g), and high birth weight (HBW, birth weight ≥ 4, 000 g). Every group contained 2 (66.7%) male infants and 1 (33.3%) female infant. Overall, the gestational age was consistent between the groups. However, significant differences in length, and placental weight were observed among the groups.

    Overall, 6, 428 (23.3%) differentially methylated regions (DMRs) were found in the cord blood of the HBW group; while 7, 791 (28.3%), 3, 753 (13.6%), and 2, 668 (9.67%) DMRs were identified in the placental DNA of the HBW group, the cord blood of the LBW group, and the placental DNA of the LBW group, respectively. Most of the differentially methylated regions were hypermethylated and were located in CpG islands (Supplement Table 1, available in www.besjournal.com). The DMRs were located in 5, 430 (37.2%), 6, 328 (43.3%), 3, 321 (22.7%), and 2, 459 (16.8%) genes of the cord blood of the HBW group, the placental DNA of the HBW group, the cord blood of the LBW group, and the placental DNA of the LBW group, respectively (Supplement Table 1, available in www.besjournal.com).

    Table Supplement Table 1.  The probe Numbers of the Methylation Change in HBW Group and LBW Group

    ItemHBWLBW
    Cord bloodPlacentaCord bloodPlacenta
    DMRs6, 4287, 7913, 7532, 668
    The number of located genes5, 4306, 3283, 3212, 459
    Percent of total probes23.3%28.3%13.6%9.67%
    Up-regulation in methylation5, 6046, 4043, 2161, 894
    CpG island4, 7076, 2192, 0921, 842
    Non-CpG i8971851, 12452
    Down-regulation in methylation8241, 387537774
    CpG island398653331459
    Non-CpG i426734206315
      Note.DMRs, differentially methylated regions.

    According to KEGG analysis, differentially methylated genes in HBW and LBW groups were enriched in hundreds of pathways compared to NBW group. We identified more than ten pathways related to glucose and lipid metabolism (Table 2).

    Table 2.  Differentially methylation genes numbers in the pathways in HBW and LBW groups

    PathwayLBWHBW
    Cord BloodPlacentaCord BloodPlacenta
    HyperHypoHyperHypoHyperHypoHyperHypo
    Metabolism pathway16725129393143735072
    Lipidmetabolism
     Fatty acid metabolism0000100180
     Glycerolipid metabolism0000140160
    Carbohydrate metabolism
     Glycolysis/Gluconeogenesis13000170200
     MAPK signaling pathway4493716871310525
     Insulin signaling pathway3162075395114
     Type 2 DM pathway10070160147
     PPAR signaling pathway11090165220
     MODY00009080
     mTOR signaling pathway10000165150
     Oxidation Phosphorylation pathway180190320410
     TCA cycle000080130
     Adipocytokine signaling pathway0000230237

    A network model demonstrating the relationships among the pathways was drawn using CytoScape software. The oxidation phosphorylation pathway was excluded from the network model. Meanwhile, we found that the insulin signaling pathway (ISP), adipocytokine signaling pathway (ASP) and MAPK signaling pathways were located in the core of network (Figure 1).

    Figure 1.  Pathway network model. ASP: Adipocytokine signaling pathway, GG: Glycolysis/Gluconeogenesis, GLM: Glycerolipid metabolism, FAM: Fatty acid metabolism, MAPK: MAPK signaling pathway, MODY: Maturity onset diabetes of the young, mTOR: mTOR signaling pathway, PPAR: PPAR signaling pathway, ISP: Insulin signaling pathway, TCA: TCA cycle

    Intrauterine life playing an important role in determining a child's susceptibility to obesity and type 2 diabetes. However, the molecular mechanisms linking fetal life and the long-term increased risk of obesity and type 2 diabetes are poorly understood. Epigenetic changes such as DNA methylation could be one of the molecular mechanisms involved. This study investigated the methylation state of approximately 14, 000 CGIs in the promoter regions of genes spread throughout the genome of different birth weight groups. Many findings demonstrate the central importance of AKT signaling to insulin sensitivity. In our study, the AKT locus is hypermethylated in the cord blood of the high birth weight group. Then, we spectulated that the expression of AKT may be inhibited in high birth weight infants in our study.

    Activated Akt is required for insulin-stimulated glucose transport via several mechanisms. In this study, we found that the PI3K/AKT locus was noticeably hypomethylated in the high birth weight group. We therefore speculated that this signal is inhibited, resulting in decreased glucose transport, increased hepatic gluconeogenesis, increased glycogen synthesis, and increased lipolysis. Thus, epigenetic regulation of the insulin signaling pathway could influence glucose metabolism in high birth weight infants.

    Activation of p38 MAPK pathways results in fatty acid oxidation and glucose uptake in skeletal muscle, and inhibition of gluconeogenesis in liver[7]. P38 MAPK plays a stimulatory role in hepatic gluconeogenesis and may contribute to the unrestrained hepatic gluconeogenesis in both type 1 and type 2 diabetes[8-9]. One study revealed that epigenetic changes in p38 MAPK are involved in the development of diabetic complications[10]. In the current study, genes encoding p38 MAPK signaling components are hypermethylated in the experimental groups. Thus, in the HBW and LBW groups, the p38 MAPK pathway and hepatic gluconeogenesis may be inhibited, potentially altering glucose metabolism.

    Leptin is involved in glucose metabolism. In this study, the LEP CpG island is generally unmethylated in placental tissue in the HBW group, confirming our speculation that the level of leptin in the cord blood of the high birth weight group is higher than that of the control group (unpublished result). Higher DNA methylation levels were observed at the LEPR promoter in the placenta and cord blood of the high birth weight group, indicating that LEPR expression may be inhibited. Thus, the LEP pathway is inhibited in the high birth weight group. Our study reveals that glucose metabolic genes are epigenetically regulated in infants of different birth weights. However, the number of infants involved in this study was limited, and further experiments describing the expression of the genes should be performed.

    • We thank all the participants for their participation and contribution.

参考文献 (10)

目录

    /

    返回文章
    返回